FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157311916> ?p ?o ?g. }

• W3157311916 endingPage "A39" @default.
• W3157311916 startingPage "A38" @default.
• W3157311916 abstract "Abstract Introduction The ability to be fast alert and to interact with the environment without motor impairment upon waking up, is a critical feature of natural sleep. DORAs represent a new class of insomnia medications that specifically inhibit the wake-promoting effects of orexin neuropeptides. Daridorexant is a potent and selective DORA under late stage development for the treatment of insomnia. Here, we assessed the impact of sleep-promoting doses of daridorexant on rats’ and dogs’ behaviour upon forced awakening. Zolpidem (a positive GABAA receptor modulator) was used as active comparator in rats because of its known negative impact on motor functions. Methods Rats were woken up at different time points after oral administration of daridorexant (10, 30, 100 mg/kg) or zolpidem (30, 100 mg/kg) during their inactive phase, and repeatedly subjected to two motor tasks: 1) the rotating rod test (lasting 120 sec, at each time point) assessing gross motor skills and coordination, and 2) the forepaw grip strength test assessing fine motor skills and muscle strength. Dogs were presented with food as an external, salient stimulus, three hours after administration of daridorexant in gelatin capsules (10, 30 or 90 mg/dog) during their active phase. Behaviour and signs of muscle weakness, after having woken up, were assessed by manual inspection of video recordings and concomitant electroencephalogram/electromyogram recordings. Results In both the rotarod and grip tests, daridorexant treatment had no effect on motor behavior at any dose or time point tested, while zolpidem significantly reduced the time spent on the rotarod and the grip strength in a dose and time-dependent manner (N=12/group; p&lt;0.001;) (e.g. at 30 min post-dose, time spent on the rotarod was 84, 79–89 and 10–19 sec for vehicle, daridorexant and zolpidem, respectively). Dogs treated with daridorexant were able to wake up easily upon food presentation. They behaved and ate normally and did not show any signs of muscle weakness. Conclusion The type of sleep promoted by daridorexant is surmountable in rats and dogs and similar to physiological sleep. It allows animals to easily wake up, to behave normally without motor impairment and to respond efficiently to the environmental conditions. Support (if any) Funded by Idorsia Pharmaceuticals Ltd" @default.
• W3157311916 created "2021-05-10" @default.
• W3157311916 creator A5021529062 @default.
• W3157311916 creator A5065109287 @default.
• W3157311916 creator A5079398777 @default.
• W3157311916 creator A5081843932 @default.
• W3157311916 date "2021-05-01" @default.
• W3157311916 modified "2023-10-02" @default.
• W3157311916 title "092 Effect of the dual orexin receptor antagonist (DORA) daridorexant on behaviour upon awakening in rats and dogs" @default.
• W3157311916 doi "https://doi.org/10.1093/sleep/zsab072.091" @default.
• W3157311916 hasPublicationYear "2021" @default.
• W3157311916 type Work @default.
• W3157311916 sameAs 3157311916 @default.
• W3157311916 citedByCount "0" @default.
• W3157311916 crossrefType "journal-article" @default.
• W3157311916 hasAuthorship W3157311916A5021529062 @default.
• W3157311916 hasAuthorship W3157311916A5065109287 @default.
• W3157311916 hasAuthorship W3157311916A5079398777 @default.
• W3157311916 hasAuthorship W3157311916A5081843932 @default.
• W3157311916 hasBestOaLocation W31573119161 @default.
• W3157311916 hasConcept C118303440 @default.
• W3157311916 hasConcept C126322002 @default.
• W3157311916 hasConcept C15744967 @default.
• W3157311916 hasConcept C170493617 @default.
• W3157311916 hasConcept C2777123777 @default.
• W3157311916 hasConcept C2779605129 @default.
• W3157311916 hasConcept C2779680196 @default.
• W3157311916 hasConcept C2779897013 @default.
• W3157311916 hasConcept C2781210498 @default.
• W3157311916 hasConcept C42219234 @default.
• W3157311916 hasConcept C42407357 @default.
• W3157311916 hasConcept C71924100 @default.
• W3157311916 hasConcept C98274493 @default.
• W3157311916 hasConceptScore W3157311916C118303440 @default.
• W3157311916 hasConceptScore W3157311916C126322002 @default.
• W3157311916 hasConceptScore W3157311916C15744967 @default.
• W3157311916 hasConceptScore W3157311916C170493617 @default.
• W3157311916 hasConceptScore W3157311916C2777123777 @default.
• W3157311916 hasConceptScore W3157311916C2779605129 @default.
• W3157311916 hasConceptScore W3157311916C2779680196 @default.
• W3157311916 hasConceptScore W3157311916C2779897013 @default.
• W3157311916 hasConceptScore W3157311916C2781210498 @default.
• W3157311916 hasConceptScore W3157311916C42219234 @default.
• W3157311916 hasConceptScore W3157311916C42407357 @default.
• W3157311916 hasConceptScore W3157311916C71924100 @default.
• W3157311916 hasConceptScore W3157311916C98274493 @default.
• W3157311916 hasIssue "Supplement_2" @default.
• W3157311916 hasLocation W31573119161 @default.
• W3157311916 hasOpenAccess W3157311916 @default.
• W3157311916 hasPrimaryLocation W31573119161 @default.
• W3157311916 hasRelatedWork W2066848996 @default.
• W3157311916 hasRelatedWork W2260914028 @default.
• W3157311916 hasRelatedWork W2322091572 @default.
• W3157311916 hasRelatedWork W2412868325 @default.
• W3157311916 hasRelatedWork W2582957278 @default.
• W3157311916 hasRelatedWork W2659103865 @default.
• W3157311916 hasRelatedWork W2799767117 @default.
• W3157311916 hasRelatedWork W2802144665 @default.
• W3157311916 hasRelatedWork W2988036728 @default.
• W3157311916 hasRelatedWork W3139117549 @default.
• W3157311916 hasVolume "44" @default.
• W3157311916 isParatext "false" @default.
• W3157311916 isRetracted "false" @default.
• W3157311916 magId "3157311916" @default.
• W3157311916 workType "article" @default.